Adverse Events in NMOSD Therapy.

Int J Mol Sci · 2022 · PMC9029040 · PMID 35456972

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Inebilizumab, eculizumab, and rituximab showed a trend in favour of the treatment as compared with a placebo; tolicizumab showed a trend in favour of treatment compared to azathioprine; and the data from the two RCTs on satralizumab were contradictory [ 69 ]. 10.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.